Antibody-drug conjugates: an emerging modality for the treatment of cancer

A Priori Prediction of Tumor Payload Concentrations: Preclinical Case Study with an Auristatin-Based Anti-5T4 Antibody-Drug Conjugate

(2014) Dhaval K. Shah et al.   AAPS Journal

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

(2014) Ian E Krop et al.   LANCET ONCOLOGY

A general approach to site-specific antibody drug conjugates

(2014) Feng Tian et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A Potent Anti-CD70 Antibody–Drug Conjugate Combining a Dimeric Pyrrolobenzodiazepine Drug with Site-Specific Conjugation Technology

(2013) Scott C. Jeffrey et al.   BIOCONJUGATE CHEMISTRY

SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML

(2013) M. S. Kung Sutherland et al.   BLOOD

Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer

(2013) Manfred Welslau et al.   CANCER

Advancing Antibody Drug Conjugation

(2013) Nicole M. Okeley et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Trends in Translational Medicine and Drug Targeting and Delivery: New Insights on an Old Concept—Targeted Drug Delivery with Antibody–Drug Conjugates for Cancers

(2013) J.Y. Rodney et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Site-specific antibody drug conjugates for cancer therapy

(2013) Siler Panowski et al.   mAbs

Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology

(2013) Stanley A. Roberts et al.   REGULATORY TOXICOLOGY AND PHARMACOLOGY

Preclinical safety profile of trastuzumab emtansine (T-DM1): Mechanism of action of its cytotoxic component retained with improved tolerability

(2013) Kirsten Achilles Poon et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY

Bioanalytical assay strategies for the development of antibody–drug conjugate biotherapeutics

(2013) Surinder Kaur et al.   Bioanalysis

Tissue Distribution Studies of Protein Therapeutics Using Molecular Probes: Molecular Imaging

(2012) Simon-Peter Williams   AAPS Journal

Antibody-Drug Conjugates in Cancer Therapy

(2012) Eric L. Sievers et al.   Annual Review of Medicine

A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer

(2012) Muralidhar Beeram et al.   CANCER

Catabolic Fate and Pharmacokinetic Characterization of Trastuzumab Emtansine (T-DM1): an Emphasis on Preclinical and Clinical Catabolism

(2012) Ben-Quan Shen et al.   CURRENT DRUG METABOLISM

A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine

(2012) Ian E. Krop et al.   JOURNAL OF CLINICAL ONCOLOGY

Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin

(2012) Dhaval K. Shah et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Impact of linker and conjugation chemistry on antigen binding, Fc receptor binding and thermal stability of model antibody-drug conjugates

(2012) Mauro Acchione et al.   mAbs

STEAP Proteins: From Structure to Applications in Cancer Therapy

(2012) I. M. Gomes et al.   MOLECULAR CANCER RESEARCH

The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates

(2012) H. K. Erickson et al.   MOLECULAR CANCER THERAPEUTICS

The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma

(2012) Peter D Senter et al.   NATURE BIOTECHNOLOGY

Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates

(2012) Ben-Quan Shen et al.   NATURE BIOTECHNOLOGY

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

(2012) Sunil Verma et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antibody Conjugate Therapeutics: Challenges and Potential

(2011) B. A. Teicher et al.   CLINICAL CANCER RESEARCH

A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies

(2011) M. A. Fanale et al.   CLINICAL CANCER RESEARCH

Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer

(2010) J. R. Junutula et al.   CLINICAL CANCER RESEARCH

Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer

(2010) Ian E. Krop et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy

(2010) Howard A. Burris et al.   JOURNAL OF CLINICAL ONCOLOGY

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

(2010) Anas Younes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer

(2008) J. S. de Bono et al.   CLINICAL CANCER RESEARCH

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index

(2008) Jagath R Junutula et al.   NATURE BIOTECHNOLOGY